210 related articles for article (PubMed ID: 33425994)
1. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
3. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the active constituents of Nilavembu Kudineer for viral replication inhibition against SARS-CoV-2: An approach to targeting RNA-dependent RNA polymerase (RdRp).
Kuriakose A; Nair B; Abdelgawad MA; Adewum AT; Soliman MES; Mathew B; Nath LR
J Food Biochem; 2022 Nov; 46(11):e14367. PubMed ID: 35994404
[TBL] [Abstract][Full Text] [Related]
5. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of SARS-CoV-2 3CL
Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
[TBL] [Abstract][Full Text] [Related]
7. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
Keretsu S; Bhujbal SP; Cho SJ
Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
[TBL] [Abstract][Full Text] [Related]
8. Computational Study on the Inhibitory Effect of Natural Compounds against the SARS-CoV-2 Proteins.
Jayaraj JM; Jothimani M; Palanisamy CP; Pentikäinen OT; Pannipara M; Al-Sehemi AG; Muthusamy K; Gopinath K
Bioinorg Chem Appl; 2022; 2022():8635054. PubMed ID: 35340421
[TBL] [Abstract][Full Text] [Related]
9. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
Meyer-Almes FJ
Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
[TBL] [Abstract][Full Text] [Related]
10. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.
Thirumal Kumar D; Shree Devi MS; Udhaya Kumar S; Sherlin A; Mathew A; Lakshmipriya M; Sathiyarajeswaran P; Gnanasambandan R; Siva R; Magesh R; George Priya Doss C
Adv Protein Chem Struct Biol; 2022; 129():275-379. PubMed ID: 35305722
[TBL] [Abstract][Full Text] [Related]
11. Exploring Phytochemicals of Traditional Medicinal Plants Exhibiting Inhibitory Activity Against Main Protease, Spike Glycoprotein, RNA-dependent RNA Polymerase and Non-Structural Proteins of SARS-CoV-2 Through Virtual Screening.
Nallusamy S; Mannu J; Ravikumar C; Angamuthu K; Nathan B; Nachimuthu K; Ramasamy G; Muthurajan R; Subbarayalu M; Neelakandan K
Front Pharmacol; 2021; 12():667704. PubMed ID: 34305589
[TBL] [Abstract][Full Text] [Related]
12. Structural similarities between SARS-CoV2 3CL
Bafna K; Cioffi CL; Krug RM; Montelione GT
Front Chem; 2022; 10():948553. PubMed ID: 36353143
[TBL] [Abstract][Full Text] [Related]
13.
Ram TS; Munikumar M; Raju VN; Devaraj P; Boiroju NK; Hemalatha R; Prasad PVV; Gundeti M; Sisodia BS; Pawar S; Prasad GP; Chincholikar M; Goel S; Mangal A; Gaidhani S; Srikanth N; Dhiman KS
J Ayurveda Integr Med; 2022; 13(1):100413. PubMed ID: 33654345
[TBL] [Abstract][Full Text] [Related]
14. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
15. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
16. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
17. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential binders of the main protease 3CL
Macchiagodena M; Pagliai M; Procacci P
Chem Phys Lett; 2020 Jul; 750():137489. PubMed ID: 32313296
[TBL] [Abstract][Full Text] [Related]
19. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
20. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
bioRxiv; 2020 Aug; ():. PubMed ID: 32803196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
